They find that deactivating two proteins makes chemotherapy more effective. Deia, News from Bizkaia



[ad_1]

Researchers at the Institute of Biomedical Research at Bellvitge (Iibedll) and the Catalan Institute of Oncology (ICO) have found that the deactivation of two proteins associated with tumor tissues makes chemotherapy more effective and reduces the risk of metastasis in colorectal cancer.

BARCELONA. The results of the research, led by David G. Molleví and Natalia Guillén Díaz-Maroto, are published in the journal "Clinical Cancer Research" and lay the groundwork for new therapies against colorectal cancer.

"We found that if we inactivate two proteins, called TAK1 and TGFBR1, which are involved in tumor cell-associated normal tissue signaling, tumor cells are more sensitive to chemotherapy and the tumor's metastatic capacity is reduced," Mollevi summarized.

"In a developed tumor we find different types of cells: on the one hand, those that are actually carcinogenic, and on the other, there are tumor cells, generally called stroma."

"Among them," he adds, "the most numerous are fibroblasts, which provide sustenance as a skeleton." These fibroblasts through these two proteins (TAK1 and TGFBR1) provide molecules and factors that nourish tumor cells and render them invisible. of chemotherapy. "

According to the researcher, one of the many lines of study that exist to combat cancer is to influence the interaction between the stroma and the tumor, to make it more vulnerable because it interferes in its development.

"In this way, the tumors can be treated with chemotherapy, with less chance of reappearing," he added.

"This new finding provides reasons to create new therapies against colorectal cancer, especially in the subgroup of the most abundant fibroblast tumors," concluded Molleví.

[ad_2]

Source link